We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mast Cell Biomarker Predicts Severity of Dengue

By LabMedica International staff writers
Posted on 13 May 2013
Print article
Image: Human mast cells (Photo courtesy of Madeleine Rådinger).
Image: Human mast cells (Photo courtesy of Madeleine Rådinger).
A protein produced by mast cells in the immune system may predict which people infected with dengue virus will develop life-threatening complications.

Dengue virus (DENV) spread by mosquitoes, infects as many as 390 million people worldwide each year, and is a significant health issue in tropical areas of the world including parts of Latin America and Asia, and health professionals in Florida have reported cases in recent years.

Scientists at Duke University (Durham, NC, USA) working with their colleagues at Duke-National University of Singapore investigated the role of mast cells in attacking dengue virus in humans, and identified a biomarker derived from the mast cells, that appeared to predict the most severe cases of the disease in human patients.

Samples used for the investigation were derived from patients that ranged in age from 18 to 77 years, with a mean of 40 years; 42% of samples were obtained from females, and 58% from males. Dengue positive samples were determined based on physician diagnosis as well as molecular tests including reverse transcriptase polymerase chain reaction (RT-PCR) for viral ribonucleic acid (RNA).

The dengue fever (DF) and dengue hemorrhagic fever (DHF) patient sera used in this study were previously determined to be positive for serotypes 1, 2, or 3 by RT-PCR using the OneStep RT-PCR Kit (Qiagen; Valencia, CA, USA). Enzyme-linked immunosorbent assay (ELISA) kits for the human mast cell biomarker chymase, a serine protease, were obtained from Antibodies-Online (Atlanta, GA, USA).

Patients that were diagnosed with DF or DHF showed chymase levels in serum obtained during the acute phase of infection were significantly higher than levels in the serum of either healthy controls or individuals with fever that were DENV negative by RT-PCR. DF patients displayed an increase in serum chymase that was approximately 10 times higher than in healthy individuals or DENV-negative patients while, in DHF patients, chymase levels 30 times higher than healthy controls were detected.

Soman N. Abraham, PhD, a professor at Duke University and the senior author of the study, said,” In addition to revealing a potential new way to diagnose and treat dengue infections, these finding may have much broader applicability for other infectious diseases where vascular leakage is a major pathologic outcome.” The study was published on April 30, 2013, in the journal eLife.

Related Links:
Duke University
Duke-National University of Singapore
Antibodies-Online


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.